Mutita Junking

2 Wanglang Road
Bangkok Noi, 10700, Thailand

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications

Dual bispecific protein engager-armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma.

Dual bispecific protein engager-armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: May 14, 2026

αTrop2/αCD3 bispecific protein engager-armed T cells (BATs) exhibit potent antitumor activity against nasopharyngeal carcinoma.

αTrop2/αCD3 bispecific protein engager-armed T cells (BATs) exhibit potent antitumor activity against nasopharyngeal carcinoma.

Journal: Cancer immunology, immunotherapy : CII
Published: March 10, 2026

Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.

Comparative in vitro evaluation of fourth-generation anti-GPC3 CAR T-cells in hepatocellular carcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 05, 2026

Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids.

Next-generation of mesothelin-targeted CAR-T cells secreting anti-PD-L1 scFv for potent immunotherapy against 3D patient-derived colorectal cancer organoids.

Journal: BMC medicine
Published: December 30, 2025

Next-generation CAR T cells targeting integrin αvβ6 and PD-L1 to enhance immunotherapy for cholangiocarcinoma.

Next-generation CAR T cells targeting integrin αvβ6 and PD-L1 to enhance immunotherapy for cholangiocarcinoma.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 02, 2025

Dual targeting of BCMA and B7-H3 with CAR T cells and bispecific protein engagers enhances anti-myeloma activity.

Dual targeting of BCMA and B7-H3 with CAR T cells and bispecific protein engagers enhances anti-myeloma activity.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: October 01, 2025

Self-differentiated Dendritic Cells Presenting NY-ESO-1 Prime Cytotoxic T Cells for the Treatment of Multiple Myeloma.

Self-differentiated Dendritic Cells Presenting NY-ESO-1 Prime Cytotoxic T Cells for the Treatment of Multiple Myeloma.

Journal: Anticancer research
Published: September 05, 2025

Enhanced antitumor efficacy of next-generation B7-H3 chimeric antigen receptor T cells containing CD28, CD137 and CD27 costimulatory domains in multiple myeloma.

Enhanced antitumor efficacy of next-generation B7-H3 chimeric antigen receptor T cells containing CD28, CD137 and CD27 costimulatory domains in multiple myeloma.

Journal: Cytotherapy
Published: July 29, 2025

CD138-targeted bispecific protein engager-armed T cells exhibit potent and selective cytotoxicity against multiple myeloma cells.

CD138-targeted bispecific protein engager-armed T cells exhibit potent and selective cytotoxicity against multiple myeloma cells.

Journal: International immunopharmacology
Published: June 12, 2025

Author Correction: Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.

Author Correction: Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.

Journal: Scientific reports
Published: February 06, 2025

B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma.

B7-H3 and GD2 overexpression as immunotherapeutic targets in retinoblastoma.

Journal: Scientific reports
Published: December 27, 2024

Enhancing T cell cytotoxicity in multiple myeloma with bispecific αPD-L1 × αCD3 T cell engager-armed T cells and low-dose bortezomib therapy.

Enhancing T cell cytotoxicity in multiple myeloma with bispecific αPD-L1 × αCD3 T cell engager-armed T cells and low-dose bortezomib therapy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 26, 2024
Showing 1-12 of 56

Last Updated: 09/26/2026